Anthropic IPO Marketing Expected to Start in Mid-October 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 20, 2018, the compensation committee of the Company's board of directors granted six new employees the option to purchase an aggregate of 20,670 shares of the Company's common stock and 10,360 restricted stock units. Each stock option has an exercise price per share equal to $10.75, which was the closing trading price on February 20, 2018. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, as amended, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages of development focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
